The effect of Myoinositol on the outcomes of assisted reproductive treatments in patients with polycystic ovary syndrome
Phase 3
Not yet recruiting
- Conditions
- Female infertility associated with anovulation.Female infertility associated with anovulationN97.0
- Registration Number
- IRCT20240119060732N2
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 98
Inclusion Criteria
Women with polycystic ovary syndrome according to ESHRE-ASRM criteria
Infertile women
Exclusion Criteria
Body mass index above 35
Endometriosis
Azospermia
Sever oligospermia
Hydrosalpinx
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does Myoinositol target in PCOS-related anovulation to improve ART outcomes?
How does Myoinositol compare to standard-of-care treatments like metformin in enhancing ART success rates for PCOS patients?
Which biomarkers are associated with Myoinositol response in PCOS patients undergoing assisted reproductive treatments?
What are the potential adverse events of Myoinositol supplementation in PCOS patients during ART cycles?
Are there combination therapies involving Myoinositol and other insulin sensitizers that improve PCOS infertility outcomes?